Valuation: EyePoint, Inc.

Market Cap 978M 847M 790M 727M 1.37B 93.06B 1.39B 9.28B 3.64B 46.54B 3.67B 3.59B 154B P/E 2026 *
-2.91x
P/E 2027 * -3.99x
Enterprise Value 684M 592M 552M 508M 958M 65.06B 969M 6.49B 2.54B 32.54B 2.57B 2.51B 108B EV / Sales 2026 *
297x
EV / Sales 2027 * 21.4x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+4.97%
1 week+2.42%
1 month-12.37%
3 months-11.55%
6 months-0.65%
Current year-32.95%
1 week 11.54
Extreme 11.54
13
1 month 11.54
Extreme 11.54
14.99
Current year 11.3
Extreme 11.295
18.87
1 year 9.51
Extreme 9.5101
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
42.5
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap.
10/7/26 Fiscal year

Chief Executive Officer

41,393 0.0494%
30/6/26 Fiscal year

Chief Technology Officer

14,625 0.0174%
23/3/26 Others

Chief Executive Officer

453,532 0.5478%
Change 5-day change 1-year change 3-year change Capi.($)
+4.97%+2.42%+21.77%-5.04% 978M
+4.86%-4.16%+52.13%+160.26% 995B
+1.04%-3.43%+50.60%+52.38% 614B
+0.98%-6.46%+24.85%+66.66% 431B
+1.96%-0.87%+43.02%+37.60% 353B
-0.11%-4.56%+31.59%+39.73% 293B
+2.52%-6.99%+8.08%+10.32% 245B
+4.57%+3.75%+35.07%+67.64% 210B
-4.32%-12.25%-5.97%-44.56% 210B
-2.58%-1.91%+15.06%+67.46% 168B
Average +1.25%-4.76%+27.62%+45.25% 351.92B
Weighted average by Cap. +0.67%-5.89%+36.58%+75.01%

Financials

2026 *2027 *
Net sales 2.3M 1.99M 1.86M 1.71M 3.22M 219M 3.26M 21.81M 8.55M 109M 8.64M 8.45M 363M 38.15M 33.02M 30.79M 28.33M 53.44M 3.63B 54.06M 362M 142M 1.81B 143M 140M 6.02B
Net income -319M -276M -257M -237M -447M -30.33B -452M -3.02B -1.19B -15.17B -1.2B -1.17B -50.29B -288M -249M -232M -214M -403M -27.35B -407M -2.73B -1.07B -13.68B -1.08B -1.06B -45.34B
Net Debt -294M -255M -238M -219M -412M -27.99B -417M -2.79B -1.09B -14B -1.11B -1.08B -46.41B -164M -142M -132M -121M -229M -15.56B -232M -1.55B -608M -7.78B -614M -601M -25.8B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
05/08/26 USD 12.25 +4.97% 2,449,109
04/08/26 USD 11.67 -6.04% 2,929,693
03/08/26 USD 12.42 +1.39% 1,479,461
31/07/26 USD 12.25 -4.74% 1,711,475
30/07/26 USD 12.86 +7.89% 1,561,104
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
12.25USD
Average target price
40.50USD
Spread / Average Target
+230.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock